Clinical Manifestations and Diagnosis of Acromegaly

被引:75
作者
Lugo, Gloria [1 ]
Pena, Lara [2 ]
Cordido, Fernando [1 ,3 ]
机构
[1] Univ Hosp A Coruna, Dept Endocrinol, La Coruna 15006, Spain
[2] Univ Hosp A Coruna, Dept Invest, La Coruna 15006, Spain
[3] Univ A Coruna, Dept Med, La Coruna 15006, Spain
关键词
BONE-MINERAL DENSITY; CARDIOVASCULAR RISK-FACTORS; GLUCOSE-TOLERANCE TEST; GROWTH-HORMONE; IGF-I; INCREASED PREVALENCE; VERTEBRAL FRACTURES; DISEASE-ACTIVITY; SLEEP-APNEA; GH;
D O I
10.1155/2012/540398
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acromegaly and gigantism are due to excess GH production, usually as a result of a pituitary adenoma. The incidence of acromegaly is 5 cases per million per year and the prevalence is 60 cases per million. Clinical manifestations in each patient depend on the levels of GH and IGF-I, age, tumor size, and the delay in diagnosis. Manifestations of acromegaly are varied and include acral and soft tissue overgrowth, joint pain, diabetes mellitus, hypertension, and heart and respiratory failure. Acromegaly is a disabling disease that is associated with increased morbidity and reduced life expectancy. The diagnosis is based primarily on clinical features and confirmed by measuring GH levels after oral glucose loading and the estimation of IGF-I. It has been suggested that the rate of mortality in patients with acromegaly is correlated with the degree of control of GH. Adequately treated, the relative mortality risk can be markedly reduced towards normal.
引用
收藏
页数:10
相关论文
共 72 条
[51]   Mortality and cancer incidence in acromegaly: A retrospective cohort study [J].
Orme, SM ;
Mcnally, RJQ ;
Cartwright, RA ;
Belchetz, PE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (08) :2730-2734
[52]   Growth Hormone, Ghrelin and Peptide YY Secretion after Oral Glucose Administration in Healthy and Obese Women [J].
Outeirino-Blanco, E. ;
Garcia-Buela, J. ;
Sangiao-Alvarellos, S. ;
Pertega-Diaz, S. ;
Martinez-Ramonde, T. ;
Cordido, F. .
HORMONE AND METABOLIC RESEARCH, 2011, 43 (08) :580-586
[53]   Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice [J].
Pokrajac, A. ;
Wark, G. ;
Ellis, A. R. ;
Wear, J. ;
Wieringa, G. E. ;
Trainer, P. J. .
CLINICAL ENDOCRINOLOGY, 2007, 67 (01) :65-70
[54]   Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly [J].
Puder, JJ ;
Nilavar, S ;
Post, KD ;
Freda, PU .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :1972-1978
[55]   Acromegaly, growth hormone and cancer risk [J].
Renehan, Andrew G. ;
Brennan, Bernadette M. .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (04) :639-657
[56]   Limited utility of oral glucose tolerance test in biochemically active acromegaly [J].
Ribeiro-Oliveira, Antonio, Jr. ;
Faje, Alexander T. ;
Barkan, Ariel L. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 164 (01) :17-22
[57]  
Rosario P. W., PITUITARY IN PRESS
[58]   GROWTH-HORMONE AND THE HEART [J].
SACCA, L ;
CITTADINI, A ;
FAZIO, S .
ENDOCRINE REVIEWS, 1994, 15 (05) :555-573
[59]   Ghrelin neutralization during fasting-refeeding cycle impairs the recuperation of body weight and alters hepatic energy metabolism [J].
Sangiao-Alvarellos, Susana ;
Helmling, Steffen ;
Vazquez, Maria J. ;
Klussmann, Sven ;
Cordido, Fernando .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2011, 335 (02) :177-188
[60]   Acromegalic axial arthropathy: A clinical case-control study [J].
Scarpa, R ;
De Brasi, D ;
Pivonello, R ;
Marzullo, P ;
Manguso, F ;
Sodano, A ;
Oriente, P ;
Lombardi, G ;
Colao, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :598-603